<p>Dr Reddy's Laboratories on Friday reported a multi-fold jump in consolidated net profit at Rs 706.5 crore for the third quarter ended December 31, 2021.</p>.<p>The drug major had logged a net profit of Rs 19.8 crore in the same period of 2020-21.</p>.<p>Revenues stood at Rs 5,319.7 crore during the third quarter as compared with Rs 4,929.6 crore in the same period of 2020-21, Dr Reddy's Laboratories said in a regulatory filing.</p>.<p>"We delivered a steady performance in Q3 with healthy EBITDA and strong cash generation, while continuing to invest in building a pipeline of products across businesses," Dr Reddy's Laboratories Co-Chairman and MD GV Prasad noted.</p>.<p>The company reported a low net profit in third quarter of last fiscal year as it had taken an impairment of Rs 597.2 crore during that period.</p>.<p>The impairment was taken on intangibles pertaining to certain products.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>
<p>Dr Reddy's Laboratories on Friday reported a multi-fold jump in consolidated net profit at Rs 706.5 crore for the third quarter ended December 31, 2021.</p>.<p>The drug major had logged a net profit of Rs 19.8 crore in the same period of 2020-21.</p>.<p>Revenues stood at Rs 5,319.7 crore during the third quarter as compared with Rs 4,929.6 crore in the same period of 2020-21, Dr Reddy's Laboratories said in a regulatory filing.</p>.<p>"We delivered a steady performance in Q3 with healthy EBITDA and strong cash generation, while continuing to invest in building a pipeline of products across businesses," Dr Reddy's Laboratories Co-Chairman and MD GV Prasad noted.</p>.<p>The company reported a low net profit in third quarter of last fiscal year as it had taken an impairment of Rs 597.2 crore during that period.</p>.<p>The impairment was taken on intangibles pertaining to certain products.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>